Enhertu market seen topping $16 billion by 2030

The Business Research Company says the global Enhertu market will surpass $16 billion by 2030, driven by expanded HER2-targeted use, stronger clinical outcomes and broader biomarker testing. North America and the U.S. are expected to lead the market, while HER2-low metastatic breast cancer remains the biggest indication.

Why it matters: - The Enhertu market is forecast to top $16 billion in 2030, putting it at about 4% of the projected oncology drugs market and nearly 1% of the global pharmaceuticals market. - The outlook signals continued growth for HER2-targeted cancer therapies as more patients are identified through biomarker testing and more indications win label expansion.

What happened: - The Business Research Company released its 2026 Enhertu market report with forecasts running through 2035. - The report estimates the Enhertu market will grow at an 18% compound annual growth rate through 2030. - North America is projected to be the largest region in 2030, with a market value of $7.9 billion. - The U.S. is expected to be the largest country market in 2030 at $3.5 billion. - The report breaks the market into indication, treatment line and distribution channel segments. - The source includes a free sample request and a detailed report page.

The details: - By indication, the market includes HER2-positive metastatic breast cancer, HER2-low metastatic breast cancer, HER2-mutant non-small cell lung cancer and HER2-positive metastatic gastric cancer. - HER2-low metastatic breast cancer is expected to be the largest indication segment in 2030, accounting for 57% of the market, or about $9 billion. - The HER2-positive metastatic breast cancer segment is projected to add $2 billion from 2025 to 2030. - The HER2-low metastatic breast cancer segment is projected to add $6 billion over the same period. - The HER2-mutant non-small cell lung cancer segment is projected to add $1 billion over the same period. - The HER2-positive metastatic gastric cancer segment is projected to add $1 billion over the same period. - By treatment line, the market is segmented into first-line, second-line and third-line therapy. - By distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies and retail pharmacies. - North America is forecast to grow from $3.8 billion in 2025 to $7.9 billion in 2030, a 16% CAGR. - The U.S. is forecast to grow from $1.9 billion in 2025 to $3.5 billion in 2030, a 13% CAGR.

Between the lines: - The report ties market growth to broader label approvals across HER2-targeted indications. - It also points to superior clinical outcomes versus conventional HER2 therapies as a driver of physician adoption. - Rising global cancer burden and more HER2 biomarker testing are expected to expand the pool of eligible patients. - The report says the biggest opportunities sit in HER2-positive metastatic breast cancer, HER2-low metastatic breast cancer, HER2-mutant non-small cell lung cancer and HER2-positive metastatic gastric cancer. - The company says those four segments together could contribute more than $10 billion in market value by 2030. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated graphics and tables.

What’s next: - The report expects continued market expansion through 2030 as oncology providers widen use of biomarker-driven treatment pathways. - Future growth will likely hinge on additional label expansion, broader testing access and continued clinical evidence supporting Enhertu’s use across tumor types. - The Business Research Company is offering report access and related research services through its website and contact channels.

The bottom line: - Enhertu is shaping up as one of the fastest-growing targeted oncology franchises, with HER2-low metastatic breast cancer driving much of the revenue growth through 2030.